Contact this trialFirst, we need to learn more about you.
Alkylating Agent
Sargramostim + Pembrolizumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is important because it seeks to improve response rates in first-line treatments for patients with stage 4 NSCLC without genetically targetable alterations, especially in those patients with PDL-1 <50%.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.